Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourLeaning Bullish
15 minLeaning Bullish
5 minConsolidating
Daily trend turns up above $0.64
Key levels
Resistance$3.14
Resistance$2.45
Support$1.69
Support$0.90
Latest news & SEC filings
NewsBiodexa Pharmaceuticals Gives R&D Update on eRapa and MTX240 Programs
ProductBiodexa Pharma cites advances in two main drug candidates
NewsBiodexa Pharmaceuticals to consolidate shares on an eight-to-one basis
All BDRX news →Biodexa Pharmaceuticals is a clinical-stage biopharmaceutical company based in the United Kingdom. It develops drug candidates and delivery technologies, including treatments such as eRapa and tolimidone, and seeks to license its product candidates to partners for regulatory approval and commercialization. Its operations span the United Kingdom, European Union, and United States.
Based on the company's 20-F filed Mar 27, 2026.
Nasdaq · Healthcare
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BDRX.
Start Free Trial →Valuation Verdict
OVERVALUED
Methods Used
P/B
Fair Value
$0.09
7
Moat Score
NONE
3/9
Piotroski Score
3.7
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-45.5%
3yr Revenue CAGR
N/A%
EPS Growth YoY
100%
FCF Growth YoY
-83.9%
Revenue Trend
DECLINING
SEPT Investing tracks real-time dark pool institutional trades for BDRX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:11:56 | $2.48 | 1,325 | $$3K | BUY |
| 14:53:52 | $2.38 | 1,244 | $$3K | MIDPOINT |
| 15:31:12 | $2.49 | 1,600 | $$4K | BUY |
| 15:55:42 | $2.86 | 1,100 | $$3K | SELL |
| 17:40:23 | $3.52 | 1,341 | $$5K | SELL |
5 dark pool trades shown · $$18K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Biodexa Pharmaceuticals Plc (BDRX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Biodexa Pharmaceuticals Plc (BDRX) is at $2.40, down 4.38% (-$0.11) at the Nov 11, 2026 close.
Latest BDRX news — Nov 11, 2026: Biodexa Pharmaceuticals Gives R&D Update on eRapa and MTX240 Programs · Nov 9, 2026: Biodexa Pharma cites advances in two main drug candidates
BDRX last reported on Mar 27, 2026: EPS -$0.00 vs -$0.01 expected — a beat of 90.9%.
BDRX does not currently pay a dividend.
Biodexa Pharmaceuticals Plc reported $1M of debt and $2M of cash (Dec 31, 2024).
Support: $1.69, $0.90, $0.34. Resistance: $2.45, $3.14, $3.75.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 11, 2026: Biodexa Pharmaceuticals Gives R&D Update on eRapa and MTX240 Programs · Nov 9, 2026: Biodexa Pharma cites advances in two main drug candidates · Oct 24, 2026: Biodexa Pharmaceuticals to consolidate shares on an eight-to-one basis